Emerald Health Sciences Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Emerald Health Sciences Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11118
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Emerald Health Sciences Inc (EHS) focuses to advance the development of cannabis in pharmaceutical, botanical and bioceutical applications. The company is developing EHP-101 based on cannabidiol for the treatment of multiple sclerosis (MS) and scleroderma; and EHP-102, derived from cannabigerol for the treatment of Huntington’s disease and Parkinson’s disease. It also provides cannabis oil products, which include non-psychotropic THCA (Tetrahydrocannabinolic acid) oil, and THC oil. EHS develops proprietary formulations which stimulates the endocannabinoid system. The company provides products intended to treat anxiety, sleep, inflammation, pain, arthritis, and dermatitis. EHS is headquartered in North Vancouver, British Columbia, Canada.

Emerald Health Sciences Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Emerald Health Sciences Enters into Agreement with University of Eastern Piedmont 10
Equity Offering 11
NEMUS Bioscience Raises USD1.75 Million in Private Placement of Shares 11
Emerald Health Sciences Raises USD9.6 Million in Private Placement of Shares 12
Emerald Health Sciences to Raise USD8 Million in Private Placement Shares 13
Emerald Health Therapeutics Raises USD2.3 Million in Private Placement of Units 14
Emerald Health Therapeutics Raises USD0.6 Million in Private Placement of Units 15
Acquisition 16
Emerald Health Sciences Acquires 10% Stake in VivaCell 16
Emerald Health Sciences Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Product News 18
Sep 14, 2017: Emerald Health Pharmaceuticals to Treat Life-Threatening Diseases with Novel Synthetic Cannabinoid-Derived Molecules 18
02/06/2018: Emerald Health Pharmaceuticals’ Scientific Team Publishes Evidence of Neuroprotection Using Patented Cannabinoid Derivative for Parkinson’s Disease 20
Product Approvals 21
Feb 26, 2018: Emerald Health Pharmaceuticals Granted FDA Orphan Drug Designation for Huntington’s Disease 21
Feb 15, 2018: Emerald Health Pharmaceuticals Granted European Orphan Designation for Systemic Scleroderma 22
Oct 20, 2017: Emerald Health Pharmaceuticals Granted FDA Orphan Drug Designation for Systemic Scleroderma 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Key Facts 2
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Emerald Health Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Emerald Health Sciences Enters into Agreement with University of Eastern Piedmont 10
NEMUS Bioscience Raises USD1.75 Million in Private Placement of Shares 11
Emerald Health Sciences Raises USD9.6 Million in Private Placement of Shares 12
Emerald Health Sciences to Raise USD8 Million in Private Placement Shares 13
Emerald Health Therapeutics Raises USD2.3 Million in Private Placement of Units 14
Emerald Health Therapeutics Raises USD0.6 Million in Private Placement of Units 15
Emerald Health Sciences Acquires 10% Stake in VivaCell 16
Emerald Health Sciences Inc, Subsidiaries 17

List of Figures
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Emerald Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Emerald Health Sciences Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Auris Medical Holding AG (EARS):企業の財務・戦略的SWOT分析
    Auris Medical Holding AG (EARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Statkraft AS:企業のM&A・事業提携・投資動向
    Statkraft AS - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Statkraft AS Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Difference Capital Financial Inc.:企業のM&A・事業提携・投資動向
    Difference Capital Financial Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Difference Capital Financial Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Ryoden Trading Co Ltd:企業の戦略・SWOT・財務情報
    Ryoden Trading Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Ryoden Trading Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Avesthagen Ltd-医療機器分野:企業M&A・提携分析
    Summary Avesthagen Ltd (Avesthagen) is a life science company that offers preventive personalized healthcare solutions. The company offers bio-nutrition, bio-agriculture and bio-pharmaceutical products. Its bio-nutrition products include validated bio-actives from Indian medicinal plants for prevent …
  • CK Infrastructure Holdings Ltd (1038):企業の財務・戦略的SWOT分析
    CK Infrastructure Holdings Ltd (1038) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Pilgrim’s Pride Corp (PPC):企業の財務・戦略的SWOT分析
    Pilgrim's Pride Corp (PPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Koki Holdings Co Ltd:企業の戦略的SWOT分析
    Koki Holdings Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Delta Corporation Limited:企業の戦略・SWOT・財務情報
    Delta Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Delta Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • UQM Technologies Inc (UQM):企業の財務・戦略的SWOT分析
    Summary UQM Technologies Inc (UQM) is a power system manufacturer that offers electric propulsion and generation solutions. The company’s products include fuel cell compression system, aircraft conditioning systems, full electric products, and hybrid components and generators. Its full electric prod …
  • Santen Pharmaceutical Co Ltd (4536):製薬・医療:M&Aディール及び事業提携情報
    Summary Santen Pharmaceutical Co Ltd (Santen) focuses on the research, development, manufacture and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for bacterial conjunctivitis, glaucoma, dry eye, Inflammation and others; OTC …
  • Natco Pharma Ltd (NATCOPHARM):企業の財務・戦略的SWOT分析
    Natco Pharma Ltd (NATCOPHARM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • SmarTone Telecommunications Holdings Ltd (315):企業の財務・戦略的SWOT分析
    SmarTone Telecommunications Holdings Ltd (315) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Suven Life Sciences Ltd (SUVEN):企業の財務・戦略的SWOT分析
    Summary Suven Life Sciences Ltd (Suven), formerly Suven Pharmaceuticals Pvt Ltd designs, develops, manufactures and supplies bulk actives, drug intermediates and fine chemicals. The company offers active pharmaceutical ingredient products which include aripiprazole, calcium acetate, divalproex sodiu …
  • Smiths Group plc:企業の戦略・SWOT・財務分析
    Smiths Group plc - Strategy, SWOT and Corporate Finance Report Summary Smiths Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Washington University in St Louis:製薬・医療:M&Aディール及び事業提携情報
    Summary Washington University in St Louis (WUSTL), a subsidiary of University of Washington is an educational university which provides education and research services. The university provides various courses of bachelor’s, master’s, and doctoral degrees in a wide range of traditional and interdisci …
  • Turboatom (TATM):企業の財務・戦略的SWOT分析
    Turboatom (TATM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Spectrum Brands Holdings, Inc.:企業の戦略・SWOT・財務分析
    Spectrum Brands Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Spectrum Brands Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • U-Haul International Inc:企業の戦略的SWOT分析
    U-Haul International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • PT Dirgantara Indonesia:企業の戦略・SWOT・財務情報
    PT Dirgantara Indonesia - Strategy, SWOT and Corporate Finance Report Summary PT Dirgantara Indonesia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆